Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Markers of hepatocellular carcinoma in Hep C-related cirrhosis

Anti-Hep B core antigen-positive results on serologic testing are a marker of hepatocellular carcinoma risk in Hep C virus-related cirrhosis, shows this month's Annals of Internal Medicine.

News image

fiogf49gjkf04

Previous exposure to Hepatitis B virus and occult Hepatitis B virus infection may have an role in hepatocellular carcinoma in patients with chronic liver disease related to Hepatitis C virus.

Dr Kazuki Ikeda and colleagues from Japan prospectively studied the association between antibody to Hepatitis B core antigen and clinical outcomes in patients with Hepatitis C virus-related chronic liver disease.

Hepatocellular carcinoma was diagnosed in 60% with anti-Hep B core antigen
Annals of Internal Medicine

The team assessd 872 patients with chronic Hepatitis C virus infection, of which 597 had chronic Hepatitis, and 275 had cirrhosis.

The research team measured incidence of hepatocellular carcinoma on follow-up from 1995 to 2005.

Only 846 of the 872 enrolled patients were followed up.

The team found that hepatocellular carcinoma occurred in 28% of patients.

Among patients with cirrhosis, hepatocellular carcinoma was diagnosed in 60% with anti-Hepatitis B core antigen.

The researchers noted that hepatocellular carcinoma was diagnosed in 45% without Hepatitis B virus-related serologic markers.

Of 224 patients with chronic hepatitis who had interferon monotherapy, 41% had sustained or transient disappearance of Hepatitis C virus RNA.

None of the anti-Hepatitis B core antigen-negative patients who had a virologic response to interferon therapy developed hepatocellular carcinoma.

The researchers observed that cancer was diagnosed in 4 of 37 anti-Hepatitis B core antigen -positive patients with a virologic response to interferon.

On further analysis, the team found that anti-Hepatitis B core antigen-positive results on serologic testing was an independent risk factor in patients with cirrhosis.

The researchers undertook only 1 assessment of smoking and alcohol consumption at study entry.

The team reported that they did not precisely determine the duration of smoking or alcohol use.

Dr Ikeda's team concluded, " Anti-Hepatitis B core antigen-positive results on serologic testing are a marker of high risk for hepatocellular carcinoma among patients with Hepatitis C virus-related cirrhosis."

"Interferon therapy might be less effective in preventing hepatocellular carcinoma among patients with chronic Hepatitis C who are anti-Hepatitis B core antigen-positive."

Ann Int Med 2007: 146(9): 649-56
03 May 2007

Go to top of page Email this page Email this page to a colleague

 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
c-Myc expression and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us